Eicosapentaenoic acid attenuates statin-induced ER stress and toxicity in myoblast

Biochemical and Biophysical Research Communications

Volumn 424, Issue 2, 2012, Pages 301-307

  Ohta, Masahiko ^a   Kawano, Hiroyuki ^a   Notsu, Tatsuto ^a   Naba, Hiroyasu ^a   Imada, Kazunori ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

EPA; ER stress; Myoblast; Statins; Toxicity

Indexed keywords

CASPASE 3; CASPASE 7; CREATINE KINASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; ICOSAPENTAENOIC ACID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN C JUN; SIMVASTATIN; X BOX BINDING PROTEIN 1;

ARTICLE; ATTENUATION; CELL DIFFERENTIATION; CELL PROTECTION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SARCOMA CELL; SKELETAL MUSCLE;

ANIMALS; BUTYLAMINES; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; EICOSAPENTAENOIC ACID; ENDOPLASMIC RETICULUM STRESS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MYOBLASTS; PPAR GAMMA; RATS;

RATTUS;

EID: 84864304354     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.111     Document Type: Article

References (39)

1. Arora R., Liebo M., Maldonado F. Statin-induced myopathy: the two faces of Janus. J. Cardiovasc. Pharmacol. Ther. 2006, 11:105-112.
2. Baker S.K., Tarnopolsky M.A. Statin-associated neuromyotoxicity. Drugs Today 2005, 41:267-293.
3. Yano T., Kawano H., Yamashita M., Mizuguchi K., Mochizuki H., Iwamoto T. Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits. Life Sci. 1997, 61:2007-2015.
4. Durrington P.N., Bhatnagar D., Mackness M.I., Morgan J., Julier K., Khan M.A., France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001, 85:544-548.
5. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Itakura H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., Shirato K. For the Japan EPA lipid intervention study (JELIS) investigators, effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
6. Naba H., Kakinuma C., Ohnishi S., Ogihara T. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem. Biophys. Res. Commun. 2006, 340:215-220.
7. Johnson T.E., Zhang X., Shi S., Umbenhauer D.R. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol. Appl. Pharmacol. 2005, 208:210-221.
8. Sacher J., Weigl L., Werner M., Szegedi C., Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J. Pharmacol. Exp. Ther. 2005, 314:1032-1041.
9. Matzno S., Tazuya-Murayama K., Tanaka H., Yasuda S., Mishima M., Uchida T., Nakabayashi T., Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J. Pharm. Pharmacol. 2003, 55:795-802.
10. Werner M., Sacher J., Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br. J. Pharmacol. 2004, 143:715-724.
11. Mutoh T., Kumano T., Nakagawa H., Kuriyama M. Role of tyrosine phosphorylation of phospholipase C gamma1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts. FEBS Lett. 1999, 446:91-94.
12. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L., Fumagalli R., Paoletti R., Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137(Suppl. 1):S101-S109.
13. 2+-calpain and caspase-3 dependent pathway. Pharmacol. Res. 2003, 48:571-578.
14. Dichtl W., Dulak J., Frick M., Alber H.F., Schwarzacher S.P., Ares M.P., Nilsson J., Pachinger O., Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23:58-63.
15. Nishimoto T., Tozawa R., Amano Y., Wada T., Imura Y., Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol. 2003, 66:2133-2139.
16. Yoshida H. ER stress and diseases. FEBS J. 2007, 274:630-658.
17. Xu C., Bailly-Maitre B., Reed J.C. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 2005, 115:2656-2664.
18. Oyadomari S., Takeda K., Takiguchi M., Gotoh T., Matsumoto M., Wada I., Akira S., Araki E., Mori M. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc. Natl. Acad. Sci. USA 2001, 98:10845-10850.
19. Devries-Seimon T., Li Y., Yao P.M., Stone E., Wang Y., Davis R.J., Flavell R., Tabas I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell Biol. 2005, 171:61-73.
20. Kimura T., Mogi C., Tomura H., Kuwabara A., Im D.S., Sato K., Kurose H., Murakami M., Okajima F. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J. Immunol. 2008, 181:7332-7340.
21. Hofnagel O., Luechtenborg B., Weissen-Plenz G., Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim. Biophys. Acta 2007, 1771:1117-1124.
22. Belo R.S., Jamieson J.C., Wright J.A. Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts. Mol. Cell. Biochem. 1993, 126:159-167.
23. Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y., Iwaki M. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol. Cell. Biochem. 2005, 269:109-114.
24. Freeman N.E., Rusinol A.E., Linton M., Hachey D.L., Fasio S., Sinensky M.S., Thewke D. Acyl-coenzyme A: cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. J. Lipid Res. 2005, 46:1933-1943.
25. Smith H.J., Tisdale M.J. Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis 2003, 8:161-169.
26. Yano M., Kishida E., Iwasaki M., Kojo S., Masuzawa Y. Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J. Nutr. 2000, 130:1095-1101.
27. Akbar M., Calderon F., Wen Z., Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl. Acad. Sci. USA 2005, 102:10858-10863.
28. Chang J.Y., Liu L.Z. Peroxisome proliferator-activated receptor agonists prevent 25-OH-cholesterol induced c-Jun activation and cell death. BMC Pharmacol. 2001, 1:10.
29. Gupta R.A., Polk D.B., Krishna U., Israel D.A., Yan F., DuBois R.N., Peek R.M. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 2001, 276:31059-31066.
30. Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., Mihara K., Moriguchi A., Matsuoka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J. Pharmacol. Exp. Ther. 2007, 320:1087-1096.
31. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 1997, 94:4312-4317.
32. Son C., Hosoda K., Matsuda J., Fujikura J., Yonemitsu S., Iwakura H., Masuzaki H., Ogawa Y., Hayashi T., Itoh H., Nishimura H., Inoue G., Yoshimasa Y., Yamori Y., Nakao K. Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. Endocrinology 2001, 142:4189-4194.
33. Zhao Y., Chen L.H. Eicosapentaenoic acid prevents lipopolysaccharide-stimulated DNA binding of activator protein-1 and c-Jun N-terminal kinase activity. J. Nutr. Biochem. 2005, 16:78-84.
34. Cerezo-Guisado M.I., Alvarez-Barrientos A., Argent R., García-Marín L.J., Bragado M.J., Lorenzo M.J. C-Jun N-terminal protein kinase signalling pathway mediates lovastatin-induced rat brain neuroblast apoptosis. Biochim. Biophys. Acta 2007, 1771:164-176.
35. Kidd P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern. Med. Rev. 2007, 12:207-227.
36. Hagiwara S., Makita Y., Gu L., Tanimoto M., Zhang M., Nakamura S., Kaneko S., Itoh T., Gohda T., Horikoshi S., Tomino Y. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice. Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol. Dial. Transplant. 2006, 21:605-615.
37. Kato T., Shimano H., Yamamoto T., Ishikawa M., Kumadaki S., Matsuzaka T., Nakagawa Y., Yahagi N., Nakakuki M., Hasty A.H., Takeuchi Y., Kobayashi K., Takahashi A., Yatoh S., Suzuki H., Sone H., Yamada N. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 2008, 57:2382-2392.
38. Alwayn I.P., Andersson C., Zauscher B., Gura K., Nose V., Puder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005, 79:606-608.
39. DeCaterina R., Endres S., Kristensen S.D., Schmidt E.B. N-3 fatty acids and renal diseases. Am. J. Kidney Dis. 1994, 24:397-415.